Attached files

file filename
EX-31.1 - EX-31.1 - Hepion Pharmaceuticals, Inc.a16-2034_1ex31d1.htm
10-Q - 10-Q - Hepion Pharmaceuticals, Inc.a16-2034_110q.htm

Exhibit 32.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND ACTING PRINCIPAL FINANCIAL OFFICER

CONTRAVIR PHARMACEUTICALS, INC.

FORM 10-Q FOR THE QUARTER ENDED DECEMBER 31, 2015

PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

I am the Chief Executive Officer and Acting Principal Financial Officer of ContraVir Pharmaceuticals, Inc., a Delaware corporation (the “Company”). I am delivering this certificate in connection with the Form 10-Q of the Company for the quarter ended December 31, 2015 and filed with the Securities and Exchange Commission (“Form 10-Q”).

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I hereby certify that, to the best of my knowledge, the Form 10-Q fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: February 12, 2016

 

/s/ James Sapirstein

 

 

James Sapirstein

 

 

Chief Executive Officer and Director

(Principal Executive Officer and Acting Principal Financial Officer)